5 policies in 2019 will affect China’s pharmaceutical market in 2020, which mainly involve China’s national medical insurance payment and pharmaceutical product cost control.
In Premier Li’s meeting the press recently after close of the two sessions, he said, “We will largely reduce the import tariff of oncology drugs that are badly needed by the people and patients and strive to achieve zero tariff”.